课题基金 / 基金详情

Molecular And Cellular Mechanisms Of Immunodeficiency Ad

Molecular And Cellular Mechanisms Of Immunodeficiency Ad
免疫缺陷的分子和细胞机制
批准号:
6669527
负责人:
Michail Sitkovsky
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Michail Sitkovsky的其他基金

相似基金

相关文献

中文摘要
翻译
免疫细胞的正常发育和功能需要腺苷脱氨酶(ADA)活性。ADA的缺乏或低水平导致人类疾病,严重联合免疫缺陷(SCID),其特征是胸腺发育不良、T淋巴细胞耗竭和自身免疫。细胞内腺苷和脱氧腺苷的积累及其直接的光毒性被认为是ADA SCID患者中观察到的对T细胞的有害作用的原因;然而,免疫细胞对ADA缺乏症的作用的独特高易感性的机制尚未完全理解。我们提出ADA SCID患者的T细胞耗竭可以通过细胞外腺苷在ADA缺陷环境中抑制TCR信号传导来解释。检验这一假设的实验表明,腺苷,而不是脱氧腺苷,在体外抑制抗原受体(TCR)触发的T细胞活化。重要的是,在体内也观察到对基因工程ADA基因缺陷小鼠的TCR触发的T细胞活化的强烈抑制。这表明ADA SCID发病过程中T细胞耗竭的新解释是由于腺苷对T细胞活化的抑制,T细胞活化对胸腺细胞成熟、从胸腺移出和外周T细胞效应功能的过程至关重要。我们发现,在体内注射抗CD 3单克隆抗体强烈激活ADA表达小鼠的T细胞,但不是他们的ADA缺陷的同窝出生。在对照实验中,体内未活化的大部分ADA缺陷型T细胞在体外通过活化TCR交联而应答,但即使在不存在ADA抑制剂的情况下,也通过加入细胞外腺苷而抑制。此外,ADA-/- T细胞的实验结果证实,T细胞中除ADA外没有酶降解细胞外添加的腺苷。ADA+/+和ADA-/-同窝仔的这些研究允许在ADA SCID研究中使用先前不可用的对照,并表明在ADA缺乏的体内环境中腺苷对TCR介导的信号传导的损害,作为胸腺细胞和T细胞对腺苷浓度增加效应的独特易感性的额外解释。在ADA缺陷环境中,细胞外腺苷“拯救”暴露于腺苷的胸腺细胞免于TCR触发的细胞凋亡的观察结果进一步支持了ADA SCID的信号传导模型与这些条件下腺苷的细胞内光敏性。在ADA缺乏条件下,细胞外腺苷的A1、A2 a和A3受体非依赖性效应的发现表明,需要研究A2 b受体和/或其他尚未鉴定的受体参与影响ADA缺乏淋巴细胞活化的可能性。这些数据表明细胞外腺苷对分化免疫细胞以及成熟T淋巴细胞的作用的重要作用,并强调进一步需要了解淋巴细胞暴露于腺苷后的分子信号传导事件。
英文摘要
Normal development and functions of immune cells require adenosine deaminase (ADA) activity. The absence or low levels of ADA results in human disease, severe combined immunodeficiency (SCID), which is characterized by hypoplastic thymus, T lymphocyte depletion, and autoimmunity. Accumulation of intracellular adenosine and deoxyadenosine and their direct lymphotoxicity are believed to be responsible for the detrimental effects on T cells observed in ADA SCID patients; however, mechanisms of uniquely high susceptibility of immune cells to effects of ADA deficiency have not been completely understood. We proposed that T cell depletion in ADA SCID patients could be explained by inhibition of TCR signaling in the ADA-deficient environment by extracellular adenosine. Experiments to test this hypothesis revealed that adenosine, but not the deoxyadenosine, inhibits the antigen receptor (TCR)-triggered activation of T cells in vitro . Importantly, the strong inhibition of TCR-triggered activation of T cells of genetically engineered ADA gene-deficient mice was also observed in vivo. This suggests the novel explanation of T cell depletion during the pathogenesis of ADA SCID as due to inhibition by adenosine of T-cell activation critical for processes of thymocytes maturation, emigration from thymus, and T cell effector functions on periphery.. We found that in vivo injection of anti-CD3 mAb strongly activates T cells of ADA-expressing mice but not of their ADA-deficient littermates. In control experiments, the large proportion of ADA-deficient T cells not activated in vivo did respond by activation to TCR crosslinking in vitro, but were inhibited by the addition of extracellular adenosine even in the absence of ADA inhibitor. In addition, results of experiments with ADA-/- T cells confirm that no enzyme in T cells other than ADA degrades extracellularly added adenosine. These studies of ADA+/+ and ADA-/- littermates allowed for previously unavailable controls in investigations of ADA SCID and suggest impairment of TCR-mediated signaling by adenosine in an ADA-deficient environment in vivo as the additional explanation of the unique susceptibility of thymocytes and T cells to the effects of increased concentrations of adenosine. The observations of the "rescue" of adenosine-exposed thymocytes from TCR-triggered apoptosis by extracellular adenosine in ADA deficient environment provided further support of signaling model of ADA SCID vs the intracellular lymphotoxicity of adenosine in these conditions. The finding of A1, A2a and A3 receptor-independent effects of extracellular adenosine in conditions of ADA deficiency suggests the need to investigate the possibility of involvement of A2b receptor and/or other yet to be identified receptor in affecting the activation of ADA deficient lymphocytes. These data point to the important role of effects of extracellular adenosine on the differentiating immune cells as well on mature T lymphocytes and emphasize the further need in understanding of molecular signaling events that follow exposure of lymphocytes to adenosine.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Preventing the Hypoxia-Adenosinergic Inhibtion of Anti-HIV Immune Response
  • 批准号:
    8043237
  • 项目类别:
  • 资助金额:
    $28.45万
  • 财政年份:
    2010
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7100600
  • 项目类别:
  • 资助金额:
    $22.29万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
  • 批准号:
    8464014
  • 项目类别:
  • 资助金额:
    $20.15万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7409103
  • 项目类别:
  • 资助金额:
    $21.65万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
海外基金